Aldeyra Therapeutics, Inc.

NASDAQ:ALDX

Biotechnology

Healthcare
$0.90 +3.01%

+$0.06 today

Market cap
$54.28M
Beta
1.19
P/E (TTM)
-4.2
EPS (TTM)
-$0.45
52W Low $1.07High $6.18

Volume 1.45M

Average 2.13M

ALDX Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Aldeyra Therapeutics, Inc.NASDAQ: ALDX

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin growth accelerates

Q1 FY2026 selling, general & admin of $1.14T rose 37859150.7% year over year, ahead of the +9732467.6% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 48103998.5% from the prior quarter. Over 3 fiscal years it compounded at -14.5% a year.

Context

  • Selling, general & admin increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 2 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the -19.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.14T+48103998.5% QoQ
Last fiscal yearDec 2025
$9.6M-19.3% YoY
LTMMar 2026
$1.14T+9732467.6% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+37859150.7%-100.0%-37859250.7 pp
1 year-19.3%-100.0%-80.7 pp
3-year CAGR-14.5%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
9.6M USD
Year-over-year change
-19.3%
4-year CAGR
-4.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How ALDX compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +9732467.6% is the highest of 10, against a peer median of +14.2%.
  • Over three fiscal years its annual growth of -14.5% compares with a peer median of +7.4%.
ALDX Competitors
Selling, General & Admin for ALDX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$1.14T USD+9732467.6%-14.5%—
AMRNAmarin Corporation plcLTM Mar 2026$99.54M USD-33.2%-27.7%46.3%
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$37.43M USD+18.7%+65.2%—
SLNSilence Therapeutics plcLTM Mar 2026$23.59M USD—+2.2%2560.2%
ANROAlto Neuroscience, Inc.LTM Mar 2026$21.89M USD-3.6%+59.0%—
CADLCandel Therapeutics, Inc.LTM Mar 2026$20.1M USD+39.9%+8.1%—
MREOMereo BioPharma Group plcLTM Mar 2026$19.76M USD-28.1%-0.2%3951.0%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$17.4M USD+18.2%+41.6%—
GNLXGenelux CorporationLTM Mar 2026$13.37M USD+14.2%+38.8%167162.5%
ACIUAC Immune S.A.LTM Mar 2026CHF 11.38M CHF+4.4%+6.7%307.5%
CLLSCellectis S.A.LTM Mar 2026$9.18M USD+20.3%-1.1%13.5%
Peer median (excluding ALDX) —+14.2%+7.4%1433.8%

Competitors are the stored peer set for ALDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development44.94M47.31M29.46M48.22M25.66M
Selling, General & Admin11.28M15.37M13.34M11.89M9.6M
Operating Expenses56.22M62.68M42.79M60.12M35.27M
Depreciation & Amortization264.18K258.71K262.78K249.62K251.99K
EBITDA(55.77M)(60.07M)(35.21M)(53.68M)(31.69M)
EBITDA Margin—————
Operating Income(56.22M)(62.68M)(42.79M)(60.12M)(35.27M)
Operating Margin—————
Interest Income185.36K2.35M7.32M6.19M3.32M
Interest Expense1.74M1.69M2.07M1.93M1.91M
Other Income / Expenses(1.56M)655.35K5.25M4.27M1.42M
Income Before Tax(57.78M)(62.02M)(37.54M)(55.85M)(33.85M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(57.78M)(62.02M)(37.54M)(55.85M)(33.85M)
Net Margin—————
EPS (Basic)(1.07)(1.06)(0.64)(0.94)(0.56)
EPS (Diluted)(1.07)(1.06)(0.64)(0.94)(0.56)
Weighted Avg Shares54.04M58.41M58.94M59.48M60.06M
Weighted Avg Shares (Diluted)54.04M58.41M58.94M59.48M60.06M

Aldeyra Therapeutics, Inc.

NASDAQ:ALDX

Intrinsic Alpha fair value

Locked

Current Price

$0.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.